Nurix Therapeutics logo
Nurix Therapeutics
NRIX | NASDAQ
Chart Builder DCF Calculator
$14.73
-$0.75 (-4.84%)
At close: Nov 16, 2026, 4:00 PM ET
$14.92
+$0.19 (+1.29%)
After-hours: Nov 16, 2026, 7:30 PM ET

Nurix Therapeutics Company Profile

Company profile explained

Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Key Executives

Name Position
Arthur T. Sands Chief Executive Officer, President & Director
Christine Ring Chief Legal Officer, Secretary & Chief Compliance Officer
Johannes Van Houte Chief Financial Officer
Arthur Weiss Founder & Member of Scientific Advisory Board
Gwenn Hansen Chief Scientific Officer
Jason Kantor Chief Business Officer
John Kuriyan Founder & Member of Scientific Advisory Board
Pasit Phiasivongsa Chief Technical Officer
Rita Kwong Senior Accounting Manager
Wesley Burwell Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Oct 15, 2026 4 Filing
Oct 14, 2026 4 Filing
Oct 13, 2026 10-Q Quarterly Report
Oct 13, 2026 8-K Current Report
Oct 02, 2026 4 Filing
Sep 23, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 02, 2026 4 Filing
Sep 01, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
Nurix Therapeutics
Nurix Therapeutics logo
Country United States
IPO Date Jul 24, 2020
Industry Biotechnology
Sector Healthcare
Employees 317
CEO Arthur T. Sands

Contact Details

1600 Sierra Point Parkway Brisbane, California 94005 United States

Stock Details

Ticker Symbol NRIX
Exchange NASDAQ
Fiscal Year December - November
Reporting Currency USD
CIK Code 0001549595
CUSIP Number 67080M103
ISIN Number US67080M1036
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.